AstraZeneca Gains More Gene Therapy AAVs in JCR Deal Worth up to $825M

The deal gives AstraZeneca’s rare disease unit Alexion access to specialized capsids developed by the Japanese biotech JCR Pharmaceuticals for use in up to five of Alexion’s gene therapies.